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OBJECTIVE: To generate estimates of the potential number
of patients with rheumatoid arthritis (RA), who are con-
sidered candidates for etanercept in the Dutch health care
setting in order to allow an assessment of the impact of
etanercept on the annual drug budget. METHODS: A lit-
erature search on incidence and prevalence data for RA
was performed on international and Dutch literature. A
subsequent expert panel was used to 1) reach consensus
on epidemiological data to be used for the budgetary im-
pact analysis in The Netherlands, 2) validate the findings
of the literature, 3) give estimates, where we did not find
reliable data in the literature. This panel was a represen-
tative sample of Dutch rheumatologists. The budgetary
impact analysis was performed from the perspective of
the Ministry of Health. RESULTS: The total number of
registered adult patients being treated by rheumatologists
was based on a Diagnosis-Registration System (range:
30,000–60,000). The panel estimated that 98% of the
patients will receive medication (range: 29,400–58,800) and
that 7% of those patients are candidates for etanercept
(range: 2,058–4,116). The total cost for etanercept is be-
tween NLG 64,084,000 (EURO 29,080,051) and NLG
128,169,000 (EURO 58,160,557), which is based on a
twice weekly injection of NLG 299.42 (EURO 135.87).
The expected costs are between NLG 49,265,000 (EURO
22,355,482) and NLG 98,530,000 (EURO 44,710,965),
when incorporating preliminary treatment termination
and switching to a once weekly dosage. CONCLUSION:
The use of literature and an expert panel allowed us to
make a budgetary impact analysis for etanercept, which
contributed to obtaining reimbursement.
PAO7
COST-OF-ILLNESS STUDIES IN GERMANY WITH 
OSTEOPOROSIS AS EXAMPLE
Brecht JG, Schädlich PK
PAREXEL GmbH InForMed Outcomes Research & 
Pharmacoeconomics, Berlin, Germany
OBJECTIVES: To investigate the suitability of data sources
in Germany for methodologically sound and comprehen-
sive cost-of-illness studies and to demonstrate this by using
appropriate data sources to quantify the cost of illness
imposed by osteoporosis from the societal perspective.
METHODS: Secondary analysis of official and administra-
tive statistics, of structural data and of relevant publica-
tions was used to evaluate their appropriateness to estimate
direct and indirect cost incurred by osteoporosis and its se-
quelae. RESULTS: Suitable statistics are available in Ger-
many relating to the corresponding positions of the Inter-
national Classification of Diseases, 9th edition (ICD-9).
These statistics mostly cover resource use and days off
work, for example, rather than immediate costs, which can
be calculated using an adequate cost factor such as cost per
treatment day in hospital. In some cases, costs are given di-
rectly, as is the case with rehabilitation and long-term care
statistics, for example. The total annual direct and indirect
costs of osteoporosis and related fractures amounted to 4.3
billion DM in 1997. Direct costs for treatment of fractures
were corrected for non-osteoporotic causes; indirect costs
incurred by loss of productivity were discounted by 5% an-
nually. The largest part of 58% was caused by treatment in
acute hospitals and rehabilitation units. Further 15% of to-
tal costs were devoted to long-term nursing care and 13%
to outpatient care. Indirect costs due to inability to work,
early retirement and premature mortality amounted to
15% of total costs and were relatively low as compared to
other chronic diseases. CONCLUSIONS: (1) About three
quarter of the considerable costs imposed by osteoporosis
were devoted to late complications whereas cost for pre-
vention and rehabilitation were low. (2) Cost of illness can
be estimated in Germany for most of the diseases that are
classified on the 3-digit level of the ICD-9.
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Approximately 700,000 vertebral fractures occur annu-
ally in the US. However, vertebral fractures are perceived
as being inexpensive. Previous acute care cost estimates
range from approximately $2,300–$6,000. OBJECTIVE:
To estimate the acute care costs and resource intensity of
vertebral fractures in women. METHODS: The Nation-
wide Inpatient Sample (NIS) database was used to iden-
tify all admissions due to vertebral fracture (closed only,
without spinal injury: pathologic, cervical, thoracic, lum-
bar, unspecified; ICD-9 codes 733.13, 805.0x, 805.2x,
805.4x, 805.4x, 805.8x). Cases were excluded if charges
	$30,000. The NIS includes random samples of hospital
discharge abstracts across all payers from 22 states in the
US from 1997. Sampling weights were applied to create
national estimates. Charges, length-of-stay (LOS) and dis-
charge disposition were analyzed by age group. RE-
SULTS: In 1997, there were 57,807 hospital admissions
for vertebral fractures in women. Mean charges and LOS
were $8,082 and 5.7 days, respectively. Over one-third
were discharged to long-term care (LTC), another 29.4%
required other follow-up care. Patients aged 75 had
longer LOS and used more post-acute care compared to
younger patients. Overall, LOS and post-acute care for
vertebral fractures are slightly below that of hip fractures
(6.8 LOS, 49% LTC, 34% other follow-up care) and
higher versus all other types of fractures (4.9 LOS, 28%
LTC, 26% other care). CONCLUSIONS: This study sug-
gests that vertebral fractures are more expensive and re-
source intensive than previously reported. Furthermore,
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total costs may be much greater when the high levels of
post-acute care are fully captured.
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IS RESIDRONATE MORE COST-EFFECTIVE 
THAN ETIDRONATE FOR FRACTURE 
PREVENTION? A COST-UTILITY ANALYSIS
Iglesias C, Torgerson D
Centre for Health Economics and Department of Health 
Studies, University of York, York, UK
OBJECTIVE: Only hip protectors, calcium and vitamin
D therapy and bisphosphonates have been shown to re-
duce hip fractures with the latter having the more robust
evidence. Three bisphosphonate are currently widely avail-
able but at differing costs, we compared the cost-effec-
tiveness of the two least expensive compounds (etidr-
onate & residronate). METHODS: We used a Markov
model to compare costs and health states of 1000 women
aged 75 years with a prevalent vertebral fracture, and
treated with either etidronate or residronate for 3 years
and then followed through until aged 100 years. We as-
sumed treatment was only effective for the 3 years. Drug
costs were taken from MIMs, fracture costs were taken
from published estimates and uprated to 1999 prices,
with hip fracture incurring a cost of £13,000 in the first
year and £7,000 in the second year. Hip fractures were
assumed to be reduced by 58% as evidenced in the most
recent trial and 33% for non hip and non vertebral frac-
tures for the residronate treated group. For etidronate
observational data suggests that it reduces hip fractures
by 34% and non hip and non vertebral fractures by
20%. We also assumed a loss of 0.32 QALYs in the year
of fracture. RESULTS: Residronate was revealed as the
dominant therapy for treating women of 75 years with a
previous vertebral fracture. Estimates of total cost sav-
ings per patient with a moderate vertebral deformity
were £10,627 and £10,857 for residronate and etidro-
nate respectively. Similarly, QALYs per patient gained
were 7.58 and 7.56 for residronate and etidronate, re-
spectively. Sensitivity analysis confirmed the robustness
of residronate’s dominancy. CONCLUSION: In the base-
line analysis both treatments are cost saving. Residronate
even seems to be cost saving when compared with etidr-
onate. Thus, residronate therapy dominates etidronate,
that is it saves more costs and produces more QALYs.
N Charges* LOS LTC%
Other
Care**%
Overall 57,807 $8,082 5.6 34.3% 29.4%
50–64 4,116 $9,396 5.4 10.4% 24.5%
65–74 9,850 $8,661 5.5 23.0% 29.3%
75–84 24,321 $8,128 5.9 35.1% 31.0%
85 19,521 $7,455 5.7 44.2% 28.9%
*Updated to 2000 dollars by Medical Care component of CPI.
**Acute hospital, other facility, home care.
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OBJECTIVE: To determine the average annual cost of
treating carpal tunnel syndrome (CTS) in a managed care
population. METHODS: All subjects contained within
PharMetric’s Integrated Outcomes database possessing a
diagnosis of carpal tunnel syndrome (ETG  0174 or
0175) during 1996–1999 were eligible for study inclu-
sion. Patients were required to have 12 months of data
following the first (index) CTS diagnosis present. Patients
less than 18 years of age and greater than 90 years of age
were excluded. Carpal tunnel syndrome specific and total
pharmacy charges were captured for the study period.
RESULTS: 82,176 patients met the inclusion criteria.
The mean age was 46.5 years (SE  0.047), and 70.6%
of the sample was female. 82% of patients with CTS did
not require surgery. General practitioners/internal medi-
cine account for 73.0% of CTS diagnoses in a given year.
Before diagnosis, the mean annual CTS specific charges
per patient was $86.14 (SE  2.47). After diagnosis, the
mean annual CTS specific charges per patient was $1186.11
(SE  6.51). Post diagnosis, inpatient charges accounted
for 40.6% of CTS-related expenses, while outpatient and
pharmacy charges accounted for 55.5% and 1.7% re-
spectively. Oral steroid use increased slightly from
16.8% to 18.7% after diagnosis of CTS, while NSAID
use increased from 36.3% to 51.2%. Outpatient steroid
injections doubled from 5.7% to 11.9% after a diagnosis
of CTS. Soft tissue disorders and osteoarthritis were the
two comorbidities that occurred most frequently with a
diagnosis of CTS with 22.8% and 12.7%, respectively.
CONCLUSION: Patients in this study, once diagnosed
with CTS, noticed significantly increased medical ex-
penses, particularly outpatient charges. NSAIDs use and
outpatient steroid injections were the preferred modali-
ties of treatment once a diagnosis of CTS was made.
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VARIATIONS IN MEDICATION UTILIZATION IN 
AN OLDER DIABETIC POPULATION
Anderson RT, Balkrishnan R, Sevick MA, Camacho FT, 
Byerly WG
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OBJECTIVE: To examine health status factors associ-
ated with utilization of different types of antidiabetic
medication in managed-care enrolled older adults, and in
turn, to study the association between antidiabetic medi-
